206 related articles for article (PubMed ID: 38117484)
1. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
[TBL] [Abstract][Full Text] [Related]
2. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
Leu S; von Felten S; Frank S; Boulay JL; Mariani L
J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338
[TBL] [Abstract][Full Text] [Related]
3. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
Braun Y; Filipski K; Bernatz S; Baumgarten P; Roller B; Zinke J; Zeiner PS; Ilina E; Senft C; Ronellenfitsch MW; Plate KH; Bähr O; Hattingen E; Steinbach JP; Mittelbronn M; Harter PN
Neuropathol Appl Neurobiol; 2021 Apr; 47(3):379-393. PubMed ID: 33080075
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.
Javier R; Wang W; Drumm M; McCortney K; Sarkaria JN; Horbinski C
PLoS One; 2022; 17(2):e0257725. PubMed ID: 35134075
[TBL] [Abstract][Full Text] [Related]
5. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
6. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
9. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
10. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
[TBL] [Abstract][Full Text] [Related]
11. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
Paraqindes H; Mourksi NE; Ballesta S; Hedjam J; Bourdelais F; Fenouil T; Picart T; Catez F; Combe T; Ferrari A; Kielbassa J; Thomas E; Tonon L; Viari A; Attignon V; Carrere M; Perrossier J; Giraud S; Vanbelle C; Gabut M; Bergeron D; Scott MS; Castro Vega L; Magne N; Huillard E; Sanson M; Meyronet D; Diaz JJ; Ducray F; Marcel V; Durand S
Neuro Oncol; 2023 Dec; 25(12):2191-2206. PubMed ID: 37531290
[TBL] [Abstract][Full Text] [Related]
13. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
[TBL] [Abstract][Full Text] [Related]
15. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of transcriptomic profile, histology, and IDH mutation for classification of gliomas.
Tran PMH; Tran LKH; Nechtman J; Dos Santos B; Purohit S; Satter KB; Dun B; Kolhe R; Sharma S; Bollag R; She JX
Sci Rep; 2020 Nov; 10(1):20651. PubMed ID: 33244057
[TBL] [Abstract][Full Text] [Related]
17. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
[TBL] [Abstract][Full Text] [Related]
18. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
[TBL] [Abstract][Full Text] [Related]
19. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
[TBL] [Abstract][Full Text] [Related]
20. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.
Viswanath P; Radoul M; Izquierdo-Garcia JL; Luchman HA; Gregory Cairncross J; Pieper RO; Phillips JJ; Ronen SM
Cancer Metab; 2018; 6():3. PubMed ID: 29619216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
